C ells that suffer DNA damage start pumping out a previously undiscovered version of the angiogenesis promoter VEGF, as Mineur et al. report. The variant, which is tough and mobile, might help cancer cells tap new sources of blood.
Researchers have already nabbed about 10 versions of VEGF, which many cancer cells overproduce to feed their need for blood. Mineur et al. were studying the effects of UV light on cells when they stumbled across another variant that lacks three of the eight standard VEGF exons. The new version, which the researchers dubbed VEGF111, forms in cells exposed to UV radiation or DNA-breaking compounds such as camptothecin. Those results suggest that the VEGF111 results from DNA damage.
VEGF111 is short but sturdy; it lacks the region that's vulnerable to protein-slicing enzymes such as plasmin, making it harder to break down. The variant is also missing the VEGF section that interacts with the extracellular matrix (ECM). That loss might boost VEGF111's mobility because it wouldn't get snared as it diffuses through the ECM.
The researchers didn't detect the new variant in cells from healthy mice and people, or in animals dosed with UV light or camptothecin, perhaps because the variant is rare. But tumor cells transplanted into mice that received camptothecin did manufacture VEGF111. To gauge the molecule's effects on angiogenesis, the team injected mice with tumor cells that fashioned one of three VEGF versions, including VEGF111. All three types of the growth factor spurred formation of new blood vessels. These vessels covered the tumors that made the two other VEGF isoforms, but they sprouted a short distance away from growths that produced VEGF111. The reason for this difference isn't clear.
Because it's durable and forms in response to DNA damage, such as that caused by chemotherapy, VEGF111 could be a formidable foe. It might help cancer cells resist drugs, for instance. On the other hand, the molecule could spur new treatments for conditions in which angiogenesis is desperately needed, such as heart attacks and nonhealing wounds. Reference: Mineur, P., et al. 2007 . J. Cell Biol. 179:1261 -1273 Microglia to the rescue I mmune cells fi ght a losing battle against a harmful abnormal protein found in some cases of amyotrophic lateral sclerosis (ALS), as Kang and Rivest report. The fi ndings support the hypothesis that extracellular accumulations of faulty proteins trigger the disease's neural damage.
Researchers aren't sure why muscle-controlling motor neurons deteriorate in ALS. Patients with the inherited form of the disease carry mutations in the gene for the antioxidant enzyme SOD1. But how defective SOD1 causes neurodegeneration remains uncertain. One possibility is that the altered SOD1 builds up outside neurons and eventually kills them. Several studies suggest that some neighboring cells can shield neurons from the protein's ill effects. Kang and Rivest tested whether microglia, the main infection-combating cells in the brain, were protective.
The researchers transplanted bone marrow with labeled cells into two mouse strains that manufacture different forms of mutant human SOD1. In both strains, the cells swarmed from the marrow to the brain, presumably to attack the SOD1. Injecting defective SOD1 into the brains of normal animals also drew a crowd of microglia. The team found that SOD1 activated microglia, but not if the cells lacked an adapter protein called MyD88.
To probe MyD88's role, the researchers implanted bone marrow lacking the protein into mice from the two strains. In one strain, MyD88-defi ciency caused the animals to develop symptoms sooner and to die nearly two months earlier. In the other stain, however, losing MyD88 signaling had no effect on survival. It's possible that the SOD1 variant in this strain kills the animals so quickly that the transplants didn't have time to help.
The study suggests that microglia from the bone marrow protect neurons from toxic buildups of mutant SOD1. But if microglia are on the job, why do the animals still die? The researchers hypothesize that, although microglia can keep faulty SOD1 in check temporarily, the immune system eventually tires, allowing lethal amounts of the protein to accumulate. 
More blood vessels sprout on cell clusters that fashion VEGF111 (bottom).
In two strains of mice with SOD1 mutations, the brain teems with microglia from the bone marrow (yellow).
